BioSpace News Archive

Pharm Country

Research Demonstrates Novel HIT Receptor Enhances T cell Antigen Sensitivity and Elicits Superior Tumor Control

The journal Nature Medicine recently published a study in which researchers developed a novel receptor to enhance recognition of tumors by engineered T cells, addressing an underlying cause for relapsed tumors in patients after chimeric antigen receptor therapy.

January 24, 2022
·
3 min read
Policy

Merck Provides U.S. and Japan Regulatory Update for Gefapixant

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) regarding Merck’s New Drug Application (NDA) for gefapixant.

January 24, 2022
·
4 min read
FDA

Tango Therapeutics Announces Clearance of TNG908 IND by FDA and Recent Pipeline Progress Updates

Tango Therapeutics, Inc. today announced progress updates across its pipeline and recent corporate highlights.

January 24, 2022
·
8 min read
Algernon Pharmaceuticals Discloses Novel Salt Patent Strategy as Part of its Psychedelic Drug DMT Intellectual Property

Algernon Pharmaceuticals Inc. is pleased to disclose that as part of its intellectual property patent applications filed in early 2021 for AP-188 (“N,N-dimethyltryptamine” or “DMT”), the Company included novel salt forms of DMT.

January 24, 2022
·
4 min read
Drug Development

MyBiotics announces successful completion of the Phase I trial for its MBX-SD-202 whole microbiome treatment, driving an innovative path to new restoration therapies using microbiome culturing technology

MyBiotics Pharma Ltd , a clinical stage microbiome therapeutics company, today announced the successful completion of Phase I clinical trial of MBX-SD-202 whole microbiome treatment in healthy volunteers.

January 24, 2022
·
4 min read
Drug Development

Lyra Therapeutics Announces Initiation of LYR-210 Pivotal Phase 3 ENLIGHTEN Program in Surgically Naïve Chronic Rhinosinusitis Patients

Company also announces initiation of BEACON clinical study of LYR-220 in previously operated chronic rhinosinusitis patients.

January 24, 2022
·
8 min read
Business

Ocugen Inc. Announces Nirdosh Jagota, Ph.D. as Senior Vice President, Regulatory Affairs, Compliance & Safety

Ocugen, Inc. today announced the appointment of Nirdosh Jagota, Ph.D., as Senior Vice President (SVP), Regulatory Affairs, compliance and safety.

January 24, 2022
·
4 min read
Pharm Country

Starton Therapeutics Successfully Demonstrates Continuous Drug Delivery of Lenalidomide from a Transdermal Patch in an In Vivo Nonclinical Study with STAR-LLD

STAR-LLD is believed to be the first continuously delivered immunomodulatory imide drug (IMiD) in development to expand the use of lenalidomide in multiple myeloma and become the first IMiD for CLL.

January 24, 2022
·
4 min read
Business

Arbutus Announces 2022 Corporate Objectives and Provides Financial Update

Arbutus Biopharma Corporation today announced its 2022 corporate objectives and provided a financial update.

January 24, 2022
·
11 min read
Drug Development

KalVista Pharmaceuticals Announces Publication of Oral HAE Therapy KVD900 Phase 1 Data in Journal of Allergy and Clinical Immunology

KalVista Pharmaceuticals Announces Publication of Oral HAE Therapy KVD900 Phase 1 Data in Journal of Allergy and Clinical Immunology

January 24, 2022
·
4 min read